In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Voyager Therapeutics Inc (VYGR). The company’s shares opened today at $23.50.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.5% and a 50.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Voyager Therapeutics Inc with a $31.40 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.79 and a one-year low of $7.76. Currently, Voyager Therapeutics Inc has an average volume of 436.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
